MDMA and psilocybin are two psychedelics that are currently being studied and in the process of being approved in Canada and the United States for the treatment of a number of indications including PTSD, depression, anxiety, and substance use disorders.

Though they are not fully approved yet for treatment, Health Canada has recently issued a statement with the intent of revising the Special Access Programme, which allows individuals to access other regulated substances for the treatment of various health issues if other means have failed. We are in the process of collecting the information of potential candidates for applications for these treatments, should the revision to the SAP go through in early 2021.